BSX - NYSE
Boston Scientific Corporation
$47.69
+0.021%Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
At a Glance
Live SnapshotBoston Scientific Corporation Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Net Profit Margin
Strong net margins indicate efficient operations and favorable tax/interest management.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Boston Scientific Corporation Income Statement
BSX • NYSE
| Boston Scientific Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
20.1B | 16.7B | 14.2B | 12.7B | 11.9B | 9.9B | 10.7B | 9.8B | 9B | 8.4B | 7.5B | 7.4B | 7.1B | 7.2B | 7.6B | 7.8B | 8.2B | 8.1B | 8.4B | 7.8B | |
GROSS PROFIT | ||||||||||||||||||||
(6.2B) | (6.5B) | (5.4B) | (5B) | (4.4B) | (4.3B) | (3.9B) | (3.3B) | (3.2B) | (3B) | (2.8B) | (2.7B) | (2.6B) | (2.7B) | (2.9B) | (3B) | (3B) | (3B) | (3B) | (2.7B) | |
13.9B | 10.3B | 8.8B | 7.7B | 7.5B | 5.6B | 6.9B | 6.5B | 5.9B | 5.3B | 4.6B | 4.6B | 4.5B | 4.6B | 4.7B | 4.8B | 5.2B | 5.1B | 5.4B | 5.1B | |
OPERATING INCOME | ||||||||||||||||||||
(9.9B) | (7.6B) | (6.7B) | (5.9B) | (5.5B) | (5B) | (5.2B) | (4.7B) | (4.3B) | (4.1B) | (3.8B) | (3.7B) | (3.7B) | (3.6B) | (3.6B) | (3.7B) | (3.9B) | (3.8B) | (4.2B) | (3.8B) | |
(6.9B) | (6B) | (5.2B) | (4.5B) | (4.3B) | (3.8B) | (3.9B) | (3.6B) | (3.3B) | (3.1B) | (2.8B) | (2.9B) | (2.7B) | (2.5B) | (2.5B) | (2.6B) | (2.6B) | (2.6B) | (2.9B) | (2.6B) | |
(2.1B) | (1.6B) | (1.4B) | (1.3B) | (1.2B) | (1.1B) | (1.2B) | (1.1B) | (997M) | (920M) | (876M) | (817M) | (861M) | (886M) | (895M) | (939M) | (1B) | (999M) | (1.1B) | (1B) | |
4B | 2.6B | 2.2B | 1.8B | 1.9B | 601M | 1.7B | 1.7B | 1.5B | 1.2B | 790M | 845M | 871M | 994M | 1.1B | 1.1B | 1.3B | 1.3B | 1.2B | 1.2B | |
PRE-TAX INCOME | ||||||||||||||||||||
(349M) | (387M) | (272M) | (464M) | (349M) | (468M) | (513M) | (269M) | (230M) | (234M) | (241M) | (217M) | (255M) | (263M) | (276M) | (396M) | (366M) | (468M) | (570M) | (435M) | |
-349M | -280M | -250M | -454M | -345M | -465M | -483M | -266M | -225M | -229M | -236M | -212M | -249M | -258M | -269M | -383M | -359M | -421M | -491M | -368M | |
(943M) | (33M) | (46M) | (47M) | (49M) | (45M) | (65M) | (70M) | (68M) | (104M) | (51M) | (48M) | (152M) | (161M) | (181M) | (200M) | (220M) | (238M) | (225M) | (231M) | |
-586M | -353M | -196M | -683M | -846M | -680M | -1B | -315M | -592M | -1.1B | -1.4B | -1.4B | -1.1B | -5.1B | -481M | -2.1B | -2.6B | -3.3B | -1.7B | -4.8B | |
3.4B | 2.3B | 2B | 1.1B | 1.1B | -79M | 687M | 1.4B | 933M | 177M | -650M | -509M | -223M | -4.1B | 642M | -1.1B | -1.3B | -2B | -569M | -3.5B | |
NET INCOME | ||||||||||||||||||||
(493M) | (436M) | (393M) | (443M) | (36M) | (2M) | -4B | -249M | (828M) | -170M | -411M | -176M | -102M | -39M | (201M) | (2M) | -283M | (10M) | -74M | (42M) | |
2.9B | 1.9B | 1.6B | 698M | 1B | -82M | 4.7B | 1.7B | 104M | 347M | -239M | -119M | -121M | -4.1B | 441M | -1.1B | -1B | -2B | -495M | -3.6B |
SEC Filings
BSX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 18, 2026 | May 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | April 30, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 01, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 22, 2026 | April 22, 2026 | 2026 | |
S-4/A S-4/A (Amended) N/A | March 30, 2026 | March 30, 2026 | ||
8-K 8-K 2026 N/A | March 30, 2026 | March 28, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 18, 2026 | March 18, 2026 | 2026 | |
S-4 S-4 N/A | February 27, 2026 | February 27, 2026 | ||
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 |
Related Guides
Continue your BSX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.